West Pharmaceutical Services Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones06:05

DJ West Pharmaceutical Services Inc. Stock Underperforms Thursday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of West Pharmaceutical Services Inc. (WST) shed 1.71% to $338.12 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 0.60% to 5,949.17 and Dow Jones Industrial Average falling 0.47% to 43,750.86.

The stock's fall snapped a four-day winning streak.

West Pharmaceutical Services Inc. closed $75.58 short of its 52-week high ($413.70), which the company achieved on February 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Thursday, as Abbott Laboratories $(ABT)$ fell 0.61% to $115.03, Becton Dickinson & Co. $(BDX)$ fell 1.75% to $227.17, and Baxter International Inc. $(BAX)$ fell 2.85% to $31.70.

Trading volume (572,135) remained 49,457 below its 50-day average volume of 621,592.

Data source: Dow Jones Market Data, FactSet. Data compiled November 14, 2024.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

 

(END) Dow Jones Newswires

November 14, 2024 17:05 ET (22:05 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment